Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A small real-world study found that women with severe asthma saw meaningful improvements in lung function and asthma control within just months of starting tezepelumab. FEV1 percent predicted jumped from 71.7% at baseline to 88.2% by 6 months, while Asthma Control Test scores nearly doubled. Researchers say the findings support tezepelumab's effectiveness in routine clinical practice, though larger studies are needed.
A single-center observational study presented at the European Respiratory Society International Congress offers some of the first real-world evidence of tezepelumab's effectiveness in women with severe asthma. The study tracked 23 women (mean age 53.3 years) over 6 months, finding significant improvements in both lung function and asthma control — and the gains came quickly.
Patients entered the study with a heavy disease burden, averaging 7.7 outpatient exacerbations and 2 hospitalizations in the prior year. After starting tezepelumab, improvements were already evident within the first few months and were sustained through the 6-month mark.
By the Numbers:
Why it matters: Real-world data on tezepelumab remain scarce, making these findings valuable for clinicians managing severe asthma in routine practice. However, the small, all-female cohort limits generalizability — larger, longer-term studies are needed to confirm these promising results.
